REG-Lakefront Announces Initiation of €50 Million Stock Repurchase Program
Lakefront Biotherapeutics announced the launch of a €50 million share repurchase program, executable through December 31, 2026. The repurchases will be conducted in the open market via Morgan Stanley, adhering to terms approved by shareholders in April 2026.
Key figures
- Repurchase authorization
- €50 million
- Total repurchase capacity
- $150 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.